Can Quercetin Increase Claudin-4 and Improve Esophageal Barrier Function in GERD?
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
Purpose:
1. Determine if oral quercetin increases the expression of claudin-4 in the lining of the
esophagus of patients with a diagnosis of gastroesophageal reflux disease (GERD); and
2. Determine whether the increase in claudin-4 by oral quercetin is accompanied by
improvement in the barrier function and acid resistance of the lining of the esophagus
of patients with a diagnosis of gastroesophageal reflux disease (GERD)
If interested, participants will be consented and provided a questionnaire to complete as
part of the study. Participants will undergo endoscopy for routine care and will have up to 8
esophageal biopsies (small tissue samples) taken for the research study. After endoscopy,
participants will be contacted to begin a 6 week treatment period with study drug (Quercetin,
taken twice daily).
At the end of the 6 week period, participants will be scheduled to have blood drawn and to
have a follow-up endoscopy with biopsies performed for the research study.
Phase:
Phase 1
Details
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)